Lilly adds to immune drug pipeline with $2.9B Merida buyout
admin Eli Lilly and Company, a global pharmaceutical giant, announced on August 31, 2026, its strategic...
biotech
Advancements in Immunotherapy Offer New Hope for Patients with Rare and Complex Sarcoma Cancers Amidst Ongoing Research
Sarcoma, a notably rare and intricate group of cancers, presents unique challenges in diagnosis and...
Major Cell Therapy Developers Novartis and Bristol Myers Squibb Halt Autoimmune Disease Trials Amid Inflammatory Side Effects
The burgeoning field of cell therapy for autoimmune diseases has hit a significant roadblock, as...
Can Viruses Fight Cancer? What Tudriqev Means for Patients With Melanoma
The U.S. Food and Drug Administration (FDA) has granted accelerated approval to Tudriqev (vusolimogene oderparepvec-wtpg),...
Takeda’s Mimrylo Secures FDA Clearance with Broad Label, Poised for Multi-Billion Dollar Annual Revenue Opportunity
The U.S. Food and Drug Administration (FDA) has granted clearance for Mimrylo, Takeda Pharmaceutical Company’s...
Verily, NVIDIA, and NIH Pioneer Multimodal AI Integrating EHR and Genomic Data for Enhanced Disease Prediction
The frontier of artificial intelligence in healthcare has taken a significant leap forward with the...
Cancer Research Institute Unveils 2026 CLIP and Technology Impact Awards, Fueling Next-Generation Immunotherapy Breakthroughs
Every monumental stride in medical science begins not just with a profound question, but with...
The Silent Epidemic: Unraveling the Rising Tide of Lung Cancer in Never-Smokers
For decades, lung cancer has been inextricably linked with smoking, a deeply ingrained association rooted...
Cancer Research Institute Ignites Future of Immunotherapy with $2.5 Million Boost, Unveiling New Postdoctoral Fellows
The Cancer Research Institute (CRI) has announced a significant expansion of its commitment to nurturing...
Meet the 2026 STARs: Aaron Whiteley, PhD
The Cancer Research Institute (CRI) has announced the prestigious STAR (Scientists Taking Risks) award for...
